Publications

  1. DeLange JM, Cutrer FM. Our evolving understanding of migraine with aura. Curr Pain Headache Rep. 2014 Oct; 18(10):453.
    View PubMed
  2. Mathew PG, Cutrer FM. Injecting under pressure: the pain of low csf pressure headache responsive to botulinum toxin injections. Curr Neurol Neurosci Rep. 2014 Sep; 14(9):477.
  3. Cutrer FM, DeLange J. Cough, exercise, and sex headaches. Neurol Clin. 2014 May; 32(2):433-50. Epub 2014 Feb 28.
    View PubMed
  4. Smith JH, Robertson CE, Garza I, Cutrer FM. Triggerless neuralgic otalgia: a case series and systematic literature review. Cephalalgia. 2013 Aug; 33(11):914-23. Epub 2013 Feb 26.
    View PubMed
  5. Moon JS, Smith JH, Lahr BD, Cutrer FM. Longitudinal associations of migraine and depressive symptoms: a cohort analysis. Psychosomatics. 2013 Jul-Aug; 54(4):317-27. Epub 2012 Dec 27.
    View PubMed
  6. Cutrer FM, Smith JH. Human studies in the pathophysiology of migraine: genetics and functional neuroimaging. Headache. 2013 Feb; 53(2):401-12. Epub 2012 Dec 20.
    View PubMed
  7. Cutrer FM, Smith JH. 15th International Headache Congress: basic science highlights. Headache. 2012 May; 52(5):851-8. Epub 2012 Apr 05.
    View PubMed
  8. Smith JH, Butterfield JH, Cutrer FM. Primary headache syndromes in systemic mastocytosis. Cephalalgia. 2011 Nov; 31(15):1522-31. Epub 2011 Sep 29.
    View PubMed
  9. Tepper SJ, Kori SH, Goadsby PJ, Winner PK, Wang MH, Silberstein SD, Cutrer FM. MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments. Mayo Clin Proc. 2011 Oct; 86(10):948-55.
    View PubMed
  10. Smith JH, Butterfield JH, Pardanani A, DeLuca GC, Cutrer FM. Neurologic symptoms and diagnosis in adults with mast cell disease. Clin Neurol Neurosurg. 2011 Sep; 113(7):570-4. Epub 2011 Jun 12.
    View PubMed
  11. Smith JH, Cutrer FM. Numbness matters: a clinical review of trigeminal neuropathy. Cephalalgia. 2011 Jul; 31(10):1131-44. Epub 2011 May 31.
    View PubMed
  12. Rollene NL, Khan Z, Schroeder DR, Cutrer FM, Coddington CC. Migraines and ovarian hyperstimulation syndrome: a dopamine connection. Fertil Steril. 2011 Jan; 95(1):417-9.
    View PubMed
  13. Cutrer FM, Sandroni P, Wendelschafer-Crabb G. Botulinum toxin treatment of cephalalgia alopecia increases substance P and calcitonin gene-related peptide-containing cutaneous nerves in scalp. Cephalalgia. 2010 Aug; 30(8):1000-6.
    View PubMed
  14. Bartleson JD, Cutrer FM. Migraine update. Diagnosis and treatment. Minn Med. 2010 May; 93(5):36-41.
    View PubMed
  15. Cutrer FM. Pathophysiology of migraine. Semin Neurol. 2010 Apr; 30(2):120-30. Epub 2010 Mar 29.
    View PubMed
  16. Garza I, Cutrer FM. Pain relief and persistence of dysautonomic features in a patient with hemicrania continua responsive to botulinum toxin type A. Cephalalgia. 2010 Apr; 30(4):500-3. Epub 2010 Feb 01.
    View PubMed
  17. Michael Cutrer F, Martin VT. Migraine clinical diagnostic criteria. Handb Clin Neurol. 2010; 97:295-302.
    View PubMed
  18. McKenzie JA, Cutrer FM. How well do headache patients remember? A comparison of self-report measures of headache frequency and severity in patients with migraine. Headache. 2009 May; 49(5):669-72.
    View PubMed
  19. Foroozan R, Cutrer FM. Transient neurologic dysfunction in migraine. Neurol Clin. 2009 May; 27(2):361-78.
    View PubMed
  20. Cutrer FM, Charles A. The neurogenic basis of migraine. Headache. 2008 Oct; 48(9):1411-4.
    View PubMed
  21. Cutrer FM. Functional imaging in primary headache disorders. Headache. 2008 May; 48(5):704-6.
    View PubMed
  22. Cutrer FM, Huerter K. Migraine aura. Neurologist. 2007 May; 13(3):118-25.
    View PubMed
  23. Cutrer FM, Black DF. Imaging findings of migraine. Headache. 2006 Jul-Aug; 46(7):1095-107.
    View PubMed
  24. Loder E, Harrington MG, Cutrer M, Sandor P, De Vries B. Selected confirmed, probable, and exploratory migraine biomarkers. Headache. 2006 Jul-Aug; 46(7):1108-27.
    View PubMed
  25. Cutrer FM, Pittelkow MR. Cephalalgic alopecia areata: a syndrome of neuralgiform head pain and hair loss responsive to botulinum A toxin injection. Cephalalgia. 2006 Jun; 26(6):747-51.
    View PubMed
  26. Fattah QA, Cutrer FM. Cluster headache with short-lived visual symptoms. Cephalalgia. 2006 Apr; 26(4):492-3.
    View PubMed
  27. Cutrer FM. Pathophysiology of migraine. Semin Neurol. 2006 Apr; 26(2):171-80.
    View PubMed
  28. Ferrari MD, Goadsby PJ, Lipton RB, Dodick DW, Cutrer FM, McCrory D, Williams P. The use of multiattribute decision models in evaluating triptan treatment options in migraine. J Neurol. 2005 Sep; 252(9):1026-32. Epub 2005 Mar 11.
    View PubMed
  29. Black DF, Swanson JW, Eross EJ, Cutrer FM. Secondary SUNCT due to intraorbital, metastatic bronchial carcinoid. Cephalalgia. 2005 Aug; 25(8):633-5.
    View PubMed
  30. Lipton RB, Cutrer FM, Goadsby PJ, Ferrari MD, Dodick DW, McCrory D, Liberman JN, Williams P. How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians. Curr Med Res Opin 2005 Mar; 21(3):413-24.
    View PubMed
  31. Dodick DW, Lipton RB, Ferrari MD, Goadsby PJ, McCrory D, Cutrer FM, Williams P. Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR Project. Curr Pain Headache Rep. 2004 Dec; 8(6):435-42.
    View PubMed
  32. Cutrer FM, Goadsby PJ, Ferrari MD, Lipton RB, Dodick DW, McCrory D, Williams P. Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project). Clin Ther. 2004 Sep; 26(9):1533-45.
    View PubMed
  33. Cutrer FM, Boes CJ. Cough, exertional, and sex headaches. Neurol Clin. 2004 Feb; 22(1):133-49.
    View PubMed
  34. Welch KM, Cutrer FM, Goadsby PJ. Migraine pathogenesis - Neural and vascular mechanisms. Neurology. 2003 Apr 8; 60(7 Suppl 2):S9-S14.
    View PubMed
  35. Jamieson D, Cutrer FM, Goldstein J, Dayno J, Hu XH. Real-world experiences in migraine therapy with rizatriptan. Headache. 2003 Mar; 43(3):223-30.
    View PubMed
  36. Dodick DW, Lipton RB, Goadsby PJ, McCrory D, Ferrari MD, Williams P, Cutrer FM. Prioritizing triptan treatment attributes: a pilot study. Neurology. 2002; 58(Suppl 3):A129.
  37. Hadjikhani N, Sanchez del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, Kwong KW, F, Cutrer FM, Rosen BR, Tootell RBH, Sorensen GA, Moskowitz MA. Mechanisms of Migraine Aura Revealed by fMRI in: Human Visual Cortex Proc. Nat Acad Sci. 2001; 98(8):4687-92.
  38. Burstein R, Cutrer FM, Yarnitsky D. The Development of Cutaneous Allodynia During A Migraine Attack. Brain. 2000; 123(Pt 8):1703-9.
    View PubMed
  39. Cutrer FM, Mitsikostas D, Ayata G, Moskowitz MA. Attenuation by butalbital of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. Headache. 1999; 39:697-704.
    View PubMed
  40. Mitsikostas D, Sanchez del Rio M, Waeber C, Huang Z, Cutrer FM, Moskowitz MA. Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis. Br J Pharmacol. 1999; 127(3):623-30.
    View PubMed
  41. Sanchez del Rio M, Bakker D, Wu O, Agosti R, Mitsikostatas D, Ostergaard L, Wells WA, Rosen BR, Sorensen G, Moskowitz MA, Cutrer FM. Perfusion Weighted Imaging During Migraine: Spontaneous Visual Aura and Headache. Cephalagia. 1999; 19:701-7.
  42. Cutrer FM, Yu X, Ayata G, Waeber C, Moskowitz MA. Effects of U-109,291a Selective h5-HT1D Agoniston Induced Dural Plasma Extravasation and c-Fos immunoreactivity within trigeminal nucleus caudalis. Neuropharmacology. 1999; 38(7):1043-53.
    View PubMed
  43. Cutrer FM, Sorensen AG, Weisskoff RM, Ostergaard L, Sanchez del Rio M, Lee EJ, Rosen BR, Moskowitz MA. Perfusion-weighted imaging defects during spontaneous migrainous aura. Ann Neurol. 1998 Jan; 43(1):25-31.
    View PubMed
  44. Mitsikostas D, Sanchez del Rio M, Cutrer FM, Waeber C, Moskowitz MA, Sanchez del Rio M. The NMDA receptor antagonist MK-801 reduces capsaicin induced c-fos expression within rat trigeminal nucleus caudalis. Pain. 1998; 76:239-48.
    View PubMed
  45. Yu X, Cutrer FM, Moskowitz MA, Waeber C. The 5-HT1D receptor antagonist GR-127,935 reverses inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater. Neuropharmacol. 1997; 36:83-91.
  46. Cutrer FM, Moskowitz MA. The actions of valproate and neurosteroids in a model of trigeminal pain. Headache. 1996; 36:579-85.
    View PubMed
  47. Cutrer FM, Moussaoui S, Garret C, Moskowitz MA. The Non-Peptide NK1 antagonist RPR 100893 decreases c-fos expression in trigeminal nucleus caudalis following noxious chemical meningeal stimulation. Neuroscience 64; 1995; 3:741-50.
  48. Cutrer FM, Schoenfeld D, Limmroth V, Panahian N, Moskowitz MA. Suppression by the sumatriptan analogueCP-122,288 of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. Br J Pharmacol 114 987-992 1995.
  49. Lee WS, Limmroth V, Ayata C, Cutrer FM, Waeber C, Moskowitz MA. Peripheral GABAA receptor mediated effects of sodium valproate on dural plasma protein extravasation to substance P and trigeminal stimulation. Br J Pharmacol 116 1661-1667 1995.
  50. Cutrer FM, Limmroth V, Ayata G, Moskowitz MA. The suppression of c-fos expression in the trigeminal nucleus caudalis by valproate. Br J Pharmacol 116 3199-324 1995.
  51. Cutrer FM, Baloh RW. Migraine Associated Dizziness. Headache 8 1992; 32:300-4.
  52. Gaitan E, Cooksey R, Cutrer FM, et al. C-Glycosylflavones: Goitrogens in Millet. Frontiers of Thyroidology. 1987; 2:971-5.